Home › Research › Inflammation and the immune system
Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases
Eleftheria-Emmanouela Katsoulaki, Dimitrios Dimopoulos, Dimitra Hadjipavlou‐Litina. Pharmaceuticals, 2025-06-01
Topic: Amyloid, tau and blood-test diagnosis
Multitarget drugs are molecules with the ability to act simultaneously on different targets at the same time, and they have been evaluated in the last decade as a powerful tool in the development of promising therapeutics for neurodegenerative diseases. This is very useful for multifactorial diseases such as Alzheimer's, Parkinson's, and Huntington's diseases, a group of neurological disorders that induce neurodegeneration and neuroinflammation. Successful drug design for multifactorial diseases depends on an interdisciplinary and collaborative approach. The complexity of the above pathologies has clearly demonstrated that such single-target drugs are inadequate to achieve a successful therapeutic result. Furthermore, molecules hitting more than one biological target exhibit also a safer profile. In this review, we present a comprehensive knowledge of recent research on multitarget synthetic approaches to confront Alzheimer's, Parkinson's, and Huntington's neurodegenerative diseases.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Katsoulaki, E.-E., Dimopoulos, D., & Hadjipavlou‐Litina, D. (2025). Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases. Pharmaceuticals. https://doi.org/10.3390/ph18060831
Vancouver
Katsoulaki E.-E, Dimopoulos D, Hadjipavlou‐Litina D. Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases. Pharmaceuticals. 2025. doi:10.3390/ph18060831. PMID: 40573227.
BibTeX
@article{katsoulaki2025-40573227,
author = {Katsoulaki, Eleftheria-Emmanouela and Dimopoulos, Dimitrios and Hadjipavlou‐Litina, Dimitra},
title = {{Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases}},
journal = {Pharmaceuticals},
year = {2025},
doi = {10.3390/ph18060831},
pmid = {40573227},
url = {https://doi.org/10.3390/ph18060831}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The complexity of the above pathologies has clearly demonstrated that such single-target drugs are inadequate to achieve a successful therapeutic result.
Why it matters
This review discusses multitarget drugs that act on more than one biological target as a strategy for Alzheimer's, Parkinson's, and Huntington's diseases. It argues that single-target drugs are inadequate for these complex diseases but does not report a proven therapy.
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Pharmaceuticals) |
| Journal's citation record | 1 / 4 | Pharmaceuticals: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 24 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 13.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 24 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Dimitra Hadjipavlou‐Litina: h-index 58 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Aristotle University of Thessaloniki: institution h-index 560 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40573227) |
| Free to read | 2 / 2 | Free to read |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Inflammation and the immune system
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.